{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:25:10Z","timestamp":1761920710781,"version":"3.37.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40273-020-00896-5","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T02:02:57Z","timestamp":1583892177000},"page":"607-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome"],"prefix":"10.1007","volume":"38","author":[{"given":"Kelly","family":"Fust","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maschio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Mark","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Marteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Myrenfors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Feuilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,11]]},"reference":[{"issue":"4","key":"896_CR1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525\u201334.","journal-title":"Lancet Oncol."},{"issue":"4","key":"896_CR2","first-page":"517","volume":"22","author":"J Soga","year":"2003","unstructured":"Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003;22(4):517\u201330.","journal-title":"J Exp Clin Cancer Res."},{"issue":"Suppl 2","key":"896_CR3","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/annonc\/12.suppl_2.S95","volume":"12","author":"P Tomassetti","year":"2001","unstructured":"Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V, Corinaldesi R. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol. 2001;12(Suppl 2):S95\u20139.","journal-title":"Ann Oncol."},{"issue":"10","key":"896_CR4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol."},{"issue":"18","key":"896_CR5","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol."},{"issue":"3","key":"896_CR6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","volume":"25","author":"GA Kaltsas","year":"2004","unstructured":"Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458\u2013511.","journal-title":"Endocr Rev."},{"issue":"12","key":"896_CR7","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/MEG.0b013e3282294d88","volume":"19","author":"D Papadogias","year":"2007","unstructured":"Papadogias D, Makras P, Kossivakis K, Kontogeorgos G, Piaditis G, Kaltsas G. Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: a therapeutic challenge. Eur J Gastroenterol Hepatol. 2007;19(12):1154\u20139.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"2","key":"896_CR8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","volume":"95","author":"RT Jensen","year":"2012","unstructured":"Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98\u2013119.","journal-title":"Neuroendocrinology."},{"issue":"6","key":"896_CR9","first-page":"759","volume":"105","author":"M Stamatakos","year":"2010","unstructured":"Stamatakos M, Kontzoglou K, Sargedi C, Tsaknaki S, Iannescu R, Safioleas C, et al. Gastrointestinal carcinoid tumors: diagnosis and treatment. Chirurgia (Bucur). 2010;105(6):759\u201366.","journal-title":"Chirurgia (Bucur)."},{"issue":"6","key":"896_CR10","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3748\/wjg.v22.i6.2118","volume":"22","author":"MS Broder","year":"2016","unstructured":"Broder MS, Chang E, Romanus D, Cherepanov D, Neary MP. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol. 2016;22(6):2118\u201325.","journal-title":"World J Gastroenterol."},{"issue":"10","key":"896_CR11","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","volume":"69","author":"J Davar","year":"2017","unstructured":"Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017;69(10):1288\u2013304.","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"896_CR12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","volume":"101","author":"S Grozinsky-Glasberg","year":"2015","unstructured":"Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid heart disease: from pathophysiology to treatment\u2013\u2019something in the way it moves\u2019. Neuroendocrinology. 2015;101(4):263\u201373.","journal-title":"Neuroendocrinology."},{"issue":"6","key":"896_CR13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","volume":"39","author":"JP Boudreaux","year":"2010","unstructured":"Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39(6):753\u201366.","journal-title":"Pancreas."},{"issue":"1","key":"896_CR14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/jpet.107.132670","volume":"325","author":"Q Liu","year":"2008","unstructured":"Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, Yu XQ, et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther. 2008;325(1):47\u201355.","journal-title":"J Pharmacol Exp Ther."},{"issue":"10","key":"896_CR15","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/hrt.2004.040329","volume":"90","author":"DJ Fox","year":"2004","unstructured":"Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004;90(10):1224\u20138.","journal-title":"Heart."},{"issue":"6","key":"896_CR16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.6004\/jnccn.2012.0075","volume":"10","author":"MH Kulke","year":"2012","unstructured":"Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, et al. Neuroendocrine tumors. J Natl Compr Cancer Netw. 2012;10(6):724\u201364.","journal-title":"J Natl Compr Cancer Netw."},{"issue":"2","key":"896_CR17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000443168","volume":"103","author":"G Delle Fave","year":"2016","unstructured":"Delle Fave G, O\u2019Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119\u201324.","journal-title":"Neuroendocrinology."},{"key":"896_CR18","unstructured":"National Comprehensive Cancer Network. Neuroendocrine and adrenal tumors. NCCN clinical practice guidelines in oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf. Accessed 21 March 2019."},{"issue":"3","key":"896_CR19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med."},{"issue":"28","key":"896_CR20","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol."},{"issue":"9","key":"896_CR21","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","volume":"22","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068\u201380.","journal-title":"Endocr Pract."},{"issue":"5","key":"896_CR22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","volume":"48","author":"P Ruszniewski","year":"2016","unstructured":"Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, et al. Patient-reported outcomes with lanreotide autogel\/depot for carcinoid syndrome: an international observational study. Dig Liver Dis. 2016;48(5):552\u20138.","journal-title":"Dig Liver Dis."},{"issue":"4","key":"896_CR23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2036.1995.tb00396.x","volume":"9","author":"AG Harris","year":"1995","unstructured":"Harris AG, Redfern JS. Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data. Aliment Pharmacol Ther. 1995;9(4):387\u201394.","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"896_CR24","doi-asserted-by":"crossref","first-page":"R423","DOI":"10.1530\/ERC-16-0200","volume":"23","author":"GK Dimitriadis","year":"2016","unstructured":"Dimitriadis GK, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23(9):R423\u201336.","journal-title":"Endocr Relat Cancer."},{"issue":"2","key":"896_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","volume":"34","author":"MS Khan","year":"2011","unstructured":"Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release lanreotide (somatuline autogel). Aliment Pharmacol Ther. 2011;34(2):235\u201342.","journal-title":"Aliment Pharmacol Ther."},{"issue":"Suppl 7","key":"896_CR26","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","volume":"23","author":"K Oberg","year":"2012","unstructured":"Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii124\u201330.","journal-title":"Ann Oncol."},{"issue":"3","key":"896_CR27","first-page":"81","volume":"6","author":"J Strosberg","year":"2013","unstructured":"Strosberg J, Weber J, Feldman M, Goldman J, Almhanna K, Kvols L. Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. Gastrointest Cancer Res. 2013;6(3):81\u20135.","journal-title":"Gastrointest Cancer Res."},{"issue":"9","key":"896_CR28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","volume":"19","author":"JR Strosberg","year":"2014","unstructured":"Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930\u20136.","journal-title":"Oncologist."},{"issue":"15 Suppl","key":"896_CR29","doi-asserted-by":"crossref","first-page":"e14579","DOI":"10.1200\/jco.2012.30.15_suppl.e14579","volume":"30","author":"JM Weber","year":"2012","unstructured":"Weber JM, Feldman M, Kvols L, Strosberg JR. Above-label doses of octreotide-LAR in patients with metastatic small-intestinal carcinoid tumors. J Clin Oncol. 2012;30(15 Suppl):e14579.","journal-title":"J Clin Oncol."},{"issue":"2","key":"896_CR30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1758834016675803","volume":"9","author":"RP Riechelmann","year":"2017","unstructured":"Riechelmann RP, Pereira AA, Rego JF, Costa FP. Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol. 2017;9(2):127\u201337.","journal-title":"Ther Adv Med Oncol."},{"key":"896_CR31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2009.04083.x","volume":"30","author":"C Toumpanakis","year":"2009","unstructured":"Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, et al. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther. 2009;30:733\u201340.","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"896_CR32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157\u201376.","journal-title":"Neuroendocrinology."},{"issue":"12","key":"896_CR33","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1080\/00365521.2018.1531653","volume":"53","author":"E Les\u00e9n","year":"2018","unstructured":"Les\u00e9n E, Bj\u00f6rstad \u00c5, Bj\u00f6rholt I, Marlow T, Bollano E, Feuilly M, et al. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scand J Gastroenterol. 2018;53(12):1509\u201318.","journal-title":"Scand J Gastroenterol."},{"key":"896_CR34","unstructured":"European Medicines Agency. Xermelo European public assessment report. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xermelo-epar-summary-public_en.pdf. Accessed 28 Mar 2019."},{"key":"896_CR35","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Approval package for application number 208794orig1s000 (xermelo). 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208794Orig1s000Approv.pdf. Accessed 28 Mar 2019."},{"key":"896_CR36","unstructured":"Health Canada. Regulatory decision summary - xermelo. 2018. https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?linkID=RDS00469. Accessed 28 Mar 2019."},{"key":"896_CR37","unstructured":"Australian Government Therapeutic Goods Administration. Final scheduling decisions and reasons for decisions by delegates of the secretary to the department of health for matters not referred to an advisory committee (delegate-only decisions). https:\/\/www.tga.gov.au\/sites\/default\/files\/delegates-final-decisions-jan-2018.pdf. Accessed 30 Apr 2019."},{"issue":"1","key":"896_CR38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","volume":"35","author":"MH Kulke","year":"2017","unstructured":"Kulke MH, Horsch D, Caplin ME, Anthony LB, Bergsland E, Oberg K, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14\u201323.","journal-title":"J Clin Oncol."},{"issue":"12","key":"896_CR39","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.clinthera.2018.10.008","volume":"40","author":"D Cella","year":"2018","unstructured":"Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, et al. Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: Post-hoc analyses from TELESTAR. Clin Ther. 2018;40(12):2006\u201320.","journal-title":"Clin Ther."},{"issue":"11","key":"896_CR40","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","volume":"39","author":"L Anthony","year":"2017","unstructured":"Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, et al. Understanding the patient experience with carcinoid syndrome: Exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158\u201368.","journal-title":"Clin Ther."},{"issue":"3","key":"896_CR41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"JL Beaumont","year":"2012","unstructured":"Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461\u20136.","journal-title":"Pancreas."},{"key":"896_CR42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-5-18","volume":"5","author":"C Frojd","year":"2007","unstructured":"Frojd C, Larsson G, Lampic C, von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007;5:18.","journal-title":"Health Qual Life Outcomes."},{"key":"896_CR43","unstructured":"Swedish Dental and Pharmaceutical Benefits Agency. Xermelo decision for inclusion in drug benefits. https:\/\/www.tlv.se\/download\/18.76aefd0a16385647546422af\/1527077011387\/bes180517_xermelo.pdf. Accessed 25 Nov 2019."},{"key":"896_CR44","unstructured":"YolaRx Consultants. Assessment of prevalence and incidence of neuro-endocrine tumors (NETs) and carcinoid syndromes (CS) not adequately controlled by somatostatin analogs in Europe and the United States: Systematic review and target population sizing\u2014final report version 1.0 [Data on file]."},{"issue":"8","key":"896_CR45","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.ejca.2012.12.022","volume":"49","author":"CM Korse","year":"2013","unstructured":"Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer. 2013;49(8):1975\u201383.","journal-title":"Eur J Cancer."},{"key":"896_CR46","unstructured":"Statistics Sweden, 2017. http:\/\/www.scb.se\/en\/. Accessed 21 Mar 2019."},{"issue":"8","key":"896_CR47","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","volume":"26","author":"ME Caplin","year":"2015","unstructured":"Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604\u201320.","journal-title":"Ann Oncol."},{"issue":"2","key":"896_CR48","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172\u201385.","journal-title":"Neuroendocrinology."},{"issue":"3","key":"896_CR49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","volume":"25","author":"M Pavel","year":"2018","unstructured":"Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018;25(3):309\u201322.","journal-title":"Endocr Relat Cancer."},{"issue":"8","key":"896_CR50","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjcard.2010.12.025","volume":"107","author":"S Bhattacharyya","year":"2011","unstructured":"Bhattacharyya S, Toumpanakis C, Chilkunda D, Caplin ME, Davar J. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol. 2011;107(8):1221\u20136.","journal-title":"Am J Cardiol."},{"issue":"6","key":"896_CR51","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1046\/j.0007-1323.2001.01798.x","volume":"88","author":"G Westberg","year":"2001","unstructured":"Westberg G, W\u00e4ngberg B, Ahlman H, Bergh CH, Beckman-Suurk\u00fcla M, Caidahl K. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg. 2001;88(6):865\u201372.","journal-title":"Br J Surg."},{"key":"896_CR52","doi-asserted-by":"crossref","unstructured":"Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73(suppl 1):e490s.","DOI":"10.6061\/clinics\/2018\/e490s"},{"issue":"1","key":"896_CR53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-9-22","volume":"9","author":"A Hutchings","year":"2014","unstructured":"Hutchings A, Schey C, Dutton R, Achana F, Antonov K. Estimating the budget impact of orphan drugs in Sweden and France 2013\u20132020. Orphanet J Rare Dis. 2014;9(1):22.","journal-title":"Orphanet J Rare Dis."},{"key":"896_CR54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/CEOR.S155641","volume":"10","author":"RF Pollock","year":"2018","unstructured":"Pollock RF, Meckley LM. An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (ig20gly) for the management of primary immunodeficiency diseases in Switzerland. Clinicoecon Outcomes Res. 2018;10:223\u20139.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"3","key":"896_CR55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3111\/13696998.2010.505863","volume":"13","author":"TC Woodward","year":"2010","unstructured":"Woodward TC, Brown R, Sacco P, Zhang J. Budget impact model of tobramycin inhalation solution for treatment of pseudomonas aeruginosa in cystic fibrosis patients. J Med Econ. 2010;13(3):492\u20139.","journal-title":"J Med Econ."},{"issue":"9","key":"896_CR56","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/13696998.2017.1337019","volume":"20","author":"L Huynh","year":"2017","unstructured":"Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB. Cost reduction from resolution\/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. J Med Econ. 2017;20(9):945\u201351.","journal-title":"J Med Econ."},{"issue":"12","key":"896_CR57","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.clinthera.2017.10.019","volume":"39","author":"VN Joish","year":"2017","unstructured":"Joish VN, Frech F, Lapuerta P. Budgetary impact of telotristat ethyl, a novel treatment for patients with carcinoid syndrome diarrhea: a US health plan perspective. Clin Ther. 2017;39(12):2338\u201344.","journal-title":"Clin Ther."},{"key":"896_CR58","unstructured":"Institute for Clinical and Economic Review. ICER value assessment framework. https:\/\/icer-review.org\/methodology\/icers-methods\/icer-value-assessment-framework\/. Accessed 8 May 2019."},{"issue":"1","key":"896_CR59","first-page":"47","volume":"18","author":"MM Cheng","year":"2012","unstructured":"Cheng MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL. Systematic review of comparative effectiveness data for oncology orphan drugs. Am J Manag Care. 2012;18(1):47\u201362.","journal-title":"Am J Manag Care."},{"key":"896_CR60","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1750-1172-8-124","volume":"8","author":"TA Kanters","year":"2013","unstructured":"Kanters TA, de Sonneville-Koedoot C, Redekop WK, Hakkaart L. Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet J Rare Dis. 2013;8:124.","journal-title":"Orphanet J Rare Dis."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00896-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-020-00896-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00896-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:37:02Z","timestamp":1615423022000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-020-00896-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,11]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1007\/s40273-020-00896-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2020,3,11]]},"assertion":[{"value":"11 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Medical writing and editorial support was funded by Ipsen Pharma (Boulogne-Billancourt, France) in accordance with good publication practice guidelines. This study and model development was sponsored by Ipsen Pharma (Boulogne-Billancourt, France).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"KF is employed by Optum. MM and MK were formerly employed by Optum. SS has received honoraria from Ipsen Pharma and Novartis, and research funding\/fellowship support from Ipsen Pharma, Novartis, Merck EMD Serono and Pfizer. DMP has received honoraria from Advanced Accelerator Applications (AAA) and Ipsen Pharma, and research funding from Trio Medicines Ltd. FM, PM, MF are employed by Ipsen Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Where patient data can be anonymised, Ipsen will share all individual participant data that underlie the results reported in this article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available. Proposals should be submitted to DataSharing@Ipsen.com and will be assessed by a scientific review board. Data are available beginning 6\u00a0months and ending 5\u00a0years after publication; after this time, only raw data may be available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}},{"value":"KF, MM, MK, SS, DMP, FM and MF made substantial contributions to the study conception\/design or acquisition\/analysis\/interpretation of the data. KF, MM, MK, SS, DMP, FM, PM and MF drafted the publication or revised it critically for important intellectual content. MM, MK, SS, DMP, FM, PM and MF approved the manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}